Targets › LDLR
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Sep 2027.
Binds low density lipoprotein /LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. (UniProt, P01130)
Open in Phaseline: the race on LDLR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| EMS | BERLIM 25/20 ASSOCIATION SGLT2 inhibitor (empagliflozin 25 mg) combined with HMG-CoA reductase inhibitor (rosuvasta | SGLT2, LDLR | Phase 3 | Dyslipidemia Associated With Type II Diabetes Mellitus | Sep 2027 |
| Cedars-Sinai Medical Center | Vytorin Cholesterol absorption inhibitor (ezetimibe) and HMG-CoA reductase inhibitor (simvastatin) | LDLR | Phase 2 | Prostate Cancer | Feb 2028 |
Prostate Cancer (1) Dyslipidemia Associated With Type II Diabetes Mellitus (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.